L Dostálek1, M Zikan1, D Fischerova1, R Kocian1, A Germanova1, F Frühauf1, L Dusek2, J Slama1, P Dundr3, K Nemejcova3, D Cibula4. 1. Gynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University in Prague, General University Hospital in Prague, Czech Republic. 2. Institute for Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic. 3. Department of Pathology, First Faculty of Medicine, Charles University in Prague, General University Hospital in Prague, Czech Republic. 4. Gynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University in Prague, General University Hospital in Prague, Czech Republic. Electronic address: dc@davidcibula.cz.
Abstract
OBJECTIVES: The aim of this study was to assess the detection rate, false-negative rate and sensitivity of SLN in LN staging in tumors over 2cm on a large cohort of patients. METHODS: Data from patients with stages pT1a - pT2 cervical cancer who underwent surgical treatment, including SLN biopsy followed by systematic pelvic lymphadenectomy, were retrospectively analyzed. A combined technique with blue dye and radiocolloid was modified in larger tumors to inject the tracer into the residual cervical stroma. RESULTS: The study included 350 patients with stages pT1a - pT2. Macrometastases, micrometastases, and isolated tumor cells were found in 10%, 8%, and 4% of cases. Bilateral detection rate was similar in subgroups with tumors<2cm, 2-3.9cm, and ≥4cm (79%, 83%, 76%) (P=0.460). There were only two cases with false-negative SLN ultrastaging for pelvic LN status among those with bilateral SLN detection. The false negative rate was very low in all three subgroups of different tumor sizes (0.9%, 0.9%, and 0.0%; P=0.999). Sensitivity reached 96% in the whole group and was high in all three groups (93%, 93%, 100%; P=0.510). CONCLUSIONS: If the tracer application technique is adjusted in larger tumors, SLN biopsy can be equally reliable in pelvic LN staging in tumors smaller and larger than 2cm. The bilateral detection rate and false negative rate did not differ in subgroups of patients with tumors<2cm, 2-3.9cm, and ≥4cm.
OBJECTIVES: The aim of this study was to assess the detection rate, false-negative rate and sensitivity of SLN in LN staging in tumors over 2cm on a large cohort of patients. METHODS: Data from patients with stages pT1a - pT2 cervical cancer who underwent surgical treatment, including SLN biopsy followed by systematic pelvic lymphadenectomy, were retrospectively analyzed. A combined technique with blue dye and radiocolloid was modified in larger tumors to inject the tracer into the residual cervical stroma. RESULTS: The study included 350 patients with stages pT1a - pT2. Macrometastases, micrometastases, and isolated tumor cells were found in 10%, 8%, and 4% of cases. Bilateral detection rate was similar in subgroups with tumors<2cm, 2-3.9cm, and ≥4cm (79%, 83%, 76%) (P=0.460). There were only two cases with false-negative SLN ultrastaging for pelvic LN status among those with bilateral SLN detection. The false negative rate was very low in all three subgroups of different tumor sizes (0.9%, 0.9%, and 0.0%; P=0.999). Sensitivity reached 96% in the whole group and was high in all three groups (93%, 93%, 100%; P=0.510). CONCLUSIONS: If the tracer application technique is adjusted in larger tumors, SLN biopsy can be equally reliable in pelvic LN staging in tumors smaller and larger than 2cm. The bilateral detection rate and false negative rate did not differ in subgroups of patients with tumors<2cm, 2-3.9cm, and ≥4cm.
Authors: Alessandro Buda; Jvan Casarin; Michael Mueller; Francesco Fanfani; Ignacio Zapardiel; Liliana Mereu; Andrea Puppo; Elena De Ponti; Marco Adorni; Debora Ferrari; Maria Luisa Gasparri; Fabio Ghezzi; Giovanni Scambia; Andrea Papadia Journal: J Cancer Res Clin Oncol Date: 2020-11-01 Impact factor: 4.553
Authors: Nicolò Bizzarri; Pedone Anchora Luigi; Gabriella Ferrandina; Gian Franco Zannoni; Maria Vittoria Carbone; Camilla Fedele; Elena Teodorico; Valerio Gallotta; Salvatore Gueli Alletti; Vito Chiantera; Anna Fagotti; Giovanni Scambia; Francesco Fanfani Journal: J Cancer Res Clin Oncol Date: 2020-09-30 Impact factor: 4.553